Difference between revisions of "Cetuximab (Erbitux)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| + | Also known as C225. | ||
| + | |||
==General information== | ==General information== | ||
| − | Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. This results in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase, and decreased vascular endothelial growth factor production.<ref name="insert">[http://packageinserts.bms.com/pi/pi_erbitux.pdf Cetuximab (Erbitux) package insert]</ref><ref>[ | + | Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. This results in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase, and decreased vascular endothelial growth factor production.<ref name="insert">[http://packageinserts.bms.com/pi/pi_erbitux.pdf Cetuximab (Erbitux) package insert]</ref><ref>[[Media:Cetuximab.pdf | Cetuximab (Erbitux) package insert (locally hosted backup)]]</ref><ref>[http://www.erbitux.com/index.aspx Erbitux manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Basal_cell_and_squamous_cell_skin_cancer#Squamous_cell_carcinoma | Squamous cell carcinoma]] | ||
| + | *[[Colon cancer]] | ||
| + | *[[Esophageal cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/cetuximab.aspx Cetuximab (Erbitux) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/cetuximab.aspx Cetuximab (Erbitux) patient drug information (Chemocare)]</ref> |
| + | *Brief patient counseling information can be found on [http://packageinserts.bms.com/pi/pi_erbitux.pdf#page=8 page 8 of the package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/cetuximab-patient-drug-information Cetuximab (Erbitux) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cetuximab-patient-drug-information Cetuximab (Erbitux) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cetuximab-patient-drug-information Cetuximab (Erbitux) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cetuximab-patient-drug-information Cetuximab (Erbitux) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
| + | [[Category:EGFR inhibitors]] | ||
| + | [[Category:Basal cell and squamous cell skin cancer medications]] | ||
| + | [[Category:Colon cancer medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
Revision as of 05:20, 8 October 2012
Also known as C225.
General information
Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. This results in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase, and decreased vascular endothelial growth factor production.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cetuximab (Erbitux) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 8 of the package insert[1]
- Cetuximab (Erbitux) patient drug information (UpToDate)[5]